Genelux (NASDAQ:GNLX – Get Free Report) and Arvinas (NASDAQ:ARVN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of current ratings for Genelux and Arvinas, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genelux | 1 | 0 | 2 | 1 | 2.75 |
| Arvinas | 1 | 3 | 6 | 0 | 2.50 |
Genelux currently has a consensus target price of $20.00, suggesting a potential upside of 781.06%. Arvinas has a consensus target price of $15.18, suggesting a potential upside of 128.33%. Given Genelux’s stronger consensus rating and higher probable upside, research analysts clearly believe Genelux is more favorable than Arvinas.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genelux | $8,000.00 | 12,838.27 | -$32.15 million | ($0.88) | -2.58 |
| Arvinas | $262.60 million | 1.66 | -$80.80 million | ($0.24) | -27.70 |
Genelux has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
37.3% of Genelux shares are owned by institutional investors. Comparatively, 95.2% of Arvinas shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 7.3% of Arvinas shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Genelux has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Arvinas has a beta of 1.81, meaning that its share price is 81% more volatile than the S&P 500.
Profitability
This table compares Genelux and Arvinas’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Genelux | N/A | -224.99% | -146.63% |
| Arvinas | -3.45% | -2.00% | -1.43% |
Summary
Genelux beats Arvinas on 8 of the 15 factors compared between the two stocks.
About Genelux
Genelux Corporation is a clinical-stage biotechnology company focused on developing oncolytic immunotherapies for cancer. Its research centers on engineered viruses designed to target and destroy cancer cells while stimulating an immune response against tumors. The company’s lead candidate is olvimulogene nanivacirepvec, also known as Olvi-Vec, an engineered vaccinia virus being studied in clinical trials for ovarian cancer and other solid tumors. Genelux is also advancing additional candidates based on its oncolytic virus platform.
About Arvinas
Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut, that develops medicines using targeted protein degradation. Founded in 2013, the company applies its PROTAC technology to direct disease-related proteins for removal by the body’s natural protein-disposal system. Its research focuses primarily on cancer, including investigational therapies designed to target estrogen and androgen receptors. The company’s programs include vepdegestrant, an estrogen receptor degrader being developed with Pfizer for certain forms of breast cancer, as well as androgen receptor degraders being studied for prostate cancer.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.
